Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8+ T lymphocyte/Treg cell balance.

Frontiers in immunology - 1 Jan 2022

Carmenate Tania, Montalvo Galia, Lozada Sum Lai, Rodriguez Yaretnis, Ortiz Yaquelin, Díaz Claudia, Avellanet Janet, Kim Juhee, Surh Charles D, Graça Luis, León Kalet

Abstract excerpt

High doses of interleukin-2 (IL-2) have been used for the treatment of melanoma and renal cell carcinoma, but this therapy has limited efficacy, with a ~15% response rate. Remarkably, 7%-9% of patients achieve complete or long-lasting responses. Many patients treated with IL-2 experienced an expansion of regulatory T cells (Tregs), specifically the expansion of ICOS+ highly suppressive Tregs, which correlate with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Interleukin-2

Share to Melanoma

Share to Neoplasms

Share to T-Lymphocytes, Regulatory

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 36059465
DOI: 10.3389/fimmu.2022.974188
PMCID: PMC9428827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8+ T lymphocyte/Treg cell balance.PMID 36059465Read ↗

Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.Semantic proximity Read ↗

Regulatory T cell expansion by a highly CD25-dependent IL-2 mutein arrests ongoing autoimmunitySemantic proximity Read ↗

Insights into the binding recognition and computational design of IL-2 muteins with enhanced predicted binding affinity to the IL-2 receptor α.Semantic proximity Read ↗

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read ↗

An IL-2 mutein increases IL-10 and CTLA-4-dependent suppression of dendritic cells by regulatory T cellsSemantic proximity Read ↗

Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1Semantic proximity Read ↗

High-Density Wild-Type IL-2 Nanoparticles Preferentially Enhance CD8⁺ T-Cell Expansion and Reprogram the Tumor MicroenvironmentSemantic proximity Read ↗

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.Semantic proximity Read ↗

An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice.Semantic proximity Read ↗

Directed disruption of IL2 aggregation sites produces designer biologics with enhanced specificity coupled to improved production capacitySemantic proximity Read ↗

IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.Semantic proximity Read ↗

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.